BIIB Financial Facts
Fair value adjustment of contingent consideration: 3.63MDiluted earnings per share attributable to Biogen Idec Inc.: -480.84M
See Full Income Statement
Accrued expenses and other: 979.95M
Total current assets: 3.24B
See Full Balance Sheet
Earnings History for Biogen Idec Inc. (BIIB)
|
Expand Research on BIIB
| Next EPS Date | 7/23/13 *Est. | EPS Growth Rate | +40.7% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | +13.4% | Revenue Growth Rate | +8.5% *Last Qtr. |
| Average % Move 1-Wk after EPS | +3.7% |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Estimize EPS/Revs | Gd. | % Since | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 5/1/12 |
Q112 | $1.40 | $1.48 | -$0.08 | $1.29B | $1.31B | N/A / N/A | = | +74.6% | Details | |
| 1/28/13 |
Q412 | $1.40 | $1.46 | -$0.06 | $1.4B | $1.38B | N/A / N/A | = | +60% | Details | |
| 7/26/11 |
Q211 | $1.36 | $1.37 | -$0.01 | $1.21B | $1.18B | N/A / N/A | = | +125% | Details | |
| 1/31/12 |
Q411 | $1.51 | $1.49 | +$0.02 | $1.3B | $1.29B | N/A / N/A | = | +100.7% | Details | |
| 4/21/11 |
Q111 | $1.43 | $1.41 | +$0.02 | $1.2M | $1.18B | N/A / N/A | = | +170.2% | Details | |
| 10/28/11 |
Q311 | $1.61 | $1.53 | +$0.08 | $1.31B | $1.27B | $1.42 / $1.32B | = | +98.7% | Details | |
| 10/26/10 |
Q310 | $1.35 | $1.23 | +$0.12 | N/A | N/A | N/A / N/A | N/A | +290.5% | Details | |
| 2/1/11 |
Q410 | $1.42 | $1.23 | +$0.19 | $1.22B | $1.17B | N/A / N/A | = | +257.3% | Details |
